A prespecified analysis of the TAILORx trial applied an AI model reading pathology slides and clinical details to 6,735 breast cancer patients. Among those given endocrine therapy alone, the model predicted time without recurrence, with a C-index of 0.736. Within the intermediate 21-gene Recurrence Score group, patients it marked as high benefit gained 5 percentage points in five-year disease-free interval from chemotherapy.
Why it is interesting: Splitting the same patients by the 21-gene score alone found no such group; the model never saw TAILORx.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.